Introduction
V-Jun was originally discovered as the oncogenic eector of Avian Sarcoma Virus 17 (ASV 17) (Maki et al., 1987) . Based on sequence similarity to the yeast transcription factor GCN4 Jun was quickly identi®ed as a major component of the mammalian AP-1 transcription complex (Bohmann et al., 1987; Angel et al., 1988; Vogt and Bos, 1990) . Since this discovery, our knowledge about how Jun functions both in normal and in tumorigenic cells has progressed rapidly. Both v-Jun and its cellular counterpart, c-Jun, have been shown to bind speci®cally to DNA and function as regulators of transcription (Bohmann et al., 1987; Angel et al., 1988; Bos et al., 1988) . Structure function studies have shown that Jun binds to DNA as a dimer. Dimerization occurs through a structural motif called the leucine zipper. A number of dierent dimerization partners have been identi®ed including c-Jun itself, other Jun family members, Fos family members, ATF family and CREB family members (reviewed in Ransone and Verma, 1990; Vogt and Bos, 1990; Vogt and Morgan, 1990) . This diversity in dimerization allows for subtle dierences in target regulatory speci®city mediated through variations of the AP-1 recognition element. Jun can also modulate target gene expression through indirect mechanisms involving non leucine zipper interactions with proteins such as Myo D1 (Bengal et al., 1992) , the glucocorticoid response factor (SchuÈ le et al., 1990; Yang-Yen et al., 1990; Touray et al., 1991; Miner and Yamamoto, 1992; Kerppola et al., 1993) , E2A (Robinson et al., 1995) and NFkB (Stein et al., 1993a,b) . In this manner, cJun can aect the expression of target genes that do not contain AP-1 recognition elements.
The mechanisms through which Jun induces oncogenic transformation are not completely de®ned. Overexpression of c-Jun will lead to oncogenic transformation and tumor formation in the rat (SchuÈ tte et al., 1989) but not the chicken model system Wong et al., 1992) . While cJun is weakly transforming in CEF its full oncogenic potential requires structural mutations similar to those found in the original v-Jun isolate Castellazzi et al., 1990) . Presumably, these structural alterations allow v-Jun to bypass a number of dierent cellular controls which serve to regulate cJun activity.
c-Jun is at the receiving end of a number of signal transduction pathways. Activation of Jun results in changes in gene expression which ultimately aect a number of dierent cellular processes and genetic programs. These changes in gene expression result from both direct and indirect actions by Jun and its various dimerization partners. Because of the central role played by Jun in gene regulation, an extensive eort has been made to identify speci®c target genes. Several genes reponsive to c-Jun have already been identi®ed. These include matrix degrading proteins such as stromelysin, collagenase I and collagenase IV (Frisch and Morisaki, 1990; Gutman and Wasylyk, 1990; Kerr et al., 1990) , dierentiation factors such as adipocyte P2 and tyrosine hydroxylase (Herrera et al., 1989; Gizang-Ginsberg and Zi, 1990) ; and mitogenic factors such as IL-2 and proliferin (Mordacq and Linzer, 1989; Muegge et al., 1989) . More recently, several genes induced speci®cally by v-Jun have been reported (Hartl and Bister, 1995; Hadman et al., 1996) . We report here the isolation, identi®cation and initial charaterization of a target gene, JTAP-4, dierentially downregulated by v-Jun but not by c-Jun in chicken embryo ®broblasts (CEF). JTAP-4 is identical to chicken apolipoprotein A-1. Regulation of apolipoprotein A-1 by v-Jun overexpression is particularly interesting because of its role in cholesterol metabolism and its inverse association with coronary heart disease.
Results

Isolation of targets responsive to v-Jun overexpression
In order to isolate target genes deregulated in response to Jun overexpression we have generated a subtracted library and utilized a dierential screen. The previously described subtracted library (Hadman et al., 1996) was constructed such that genes upregulated by v-Jun would be enriched. We have used this library to clone another Jun target gene that we called JTAP-1 (Jun Transformation Associated Protein) (Hadman et al., 1996) . Unexpectedly, one of the clones we isolated from this library, JTAP-4, appeared to be downregulated by v-Jun. Northern blot analysis using JTAP-4 as a probe, revealed a message that was consistently underexpressed in v-Jun transformed but not c-Jun overexpressing or RCAS vector infected CEF ( Figure  1 ). To ensure that JTAP-4 was truly downregulated in v-Jun overexpressing cells, we have assayed by Northern analysis, RNA isolated from more than ®ve dierent sets of RCAS VJ-1 (v-Jun), RCAS CJ-3 (cJun) or RCAS vector infected CEF. In all cases, JTAP-4 is underexpressed 5 ± 10-fold in CEF expressing high levels of v-Jun compared with CEF overexpressing cJun or RCAS vector alone (not shown).
JTAP-4 is identical to apolipoprotein A-1
The consistent downregulation shown in Figure 1 by vJun transformed CEF demonstrates that JTAP-4 is in¯uenced in a negative manner by v-Jun overexpression. To begin characterization of this negative v-Jun target, we sequenced both ends of two independent JTAP-4 cDNA isolates. Computer homology search analysis (Geneworks, Intelligenetics) revealed JTAP-4 to be identical to chicken apolipoprotein A-1 (Figure 2) . Apolipoprotein A1 is the major component of high density lipoprotein (HDL). A strong correlation exists between decreased levels of HDL and the development of arteriosclerosis. For this reason, much eort has been applied towards understanding the physiological role of this biologically interesting protein. It has been shown that HDL is regulated at a number of dierent levels and that decreases in apolipoprotein A1 are associated with several disease states including some cancers. Our results here suggest that oncogenically activated v-Jun can drastically modulate the levels of apolipoprotein A-1 at the level of messenger RNA.
Regulation of apolipoprotein A-1 messenger RNA by v-Jun
Northern analysis in Figure 1 reveals that the steady state level of apolipoprotein A-1 (JTAP-4) message is decreased nearly 10-fold in CEF overexpressing v-Jun compared with CEF overexpressing c-Jun or RCAS vector. This change in steady state message levels could occur through a change in message stability; through a change in gene transcription; or both. We have examined message stability by analyzing the levels of apolipoprotein A-1 message present at various time points after treatment with Actinomycin D (Figure 3 ). Although the overall levels of apolipoprotein A-1 message are lower in v-Jun transformed CEF, the relative stability of the message is identical to that in normal CEF. These results suggest that the change in steady state message levels seen by Northern analysis in Figure 1 are most likely due to a decrease in apolipoprotein A-1 gene transcription. Figure 3 also demonstrates that apolipoprotein A-1 message is extremely stable in CEF with a half life of around 18 ± 20 h.
The data in Figure 3 suggest that apolipoprotein A-1 is downregulated by Jun at the level of promoter activity. To examine this possibility, we isolated a genomic clone of apolipoprotein A-1 from a chicken EMBL3 genomic library (Clontech). Because the apolipoprotein A-1 promoter has already been characterized by others (Bhattacharyya et al., 1991 Bhattacharyya and Banerjee, 1993) , we were able to quickly map and clone the gene regulatory region. We have fused a genomic fragment that extends to 76800, to the gene for chloramphenicol acetyl transferase (CAT) and assayed its activity in CEF overexpressing v-Jun, c-Jun or RCAS vector alone ( Figure 4 ). As expected, the promoter fragment was active in vector and c-Jun infected CEF but only minimally active in vJun transformed CEF (Figure 4b ). In an eort to map the promoter element(s) responsive to v-Jun, we have generated a series of 5' promoter deletion mutations (Figure 4a ). Each of these were assayed as described above in RCAS vector, c-Jun expressing and v-Jun transformed CEF (Figure 4b ). Interestingly, even in vector infected CEF, all of the deletions between 76800 and 7311 were inactive suggesting that the apolipoprotein A-1 promoter is subject to complex positive and negative regulatory controls. Deletion to 7311 resulted in the reappearance of promoter activity in vector infected and c-Jun expressing CEF, albeit at nearly 8 ± 9-fold lower activity. v-Jun overexpressing CEF, however, remained unresponsive. Because the 311 base pair promoter fragment is active in RCAS vector and to a lesser degree c-Jun expressing CEF, but remains inactive in v-Jun transformed CEF, we conclude that this fragment contains a negative element responsive to v-Jun. In c-Jun expressing CEF, the decrease in activity between the 76800 and et al., 1995) . In this manner, Jun can modulate the expression of a variety of genes both directly and indirectly. In this report, we present data showing that v-Jun overexpression has a negative in¯uence on expression of apolipoprotein A-1. Apolipoprotein A-1 is the major component of high density lipoprotein or HDL. HDL has a number of physiological functions including reverse cholesterol transport, a process by which cholesterol mobilized from peripheral tissues is transported to the liver (Eisenberg, 1984; Miller et al., 1985) . It is now well established that HDL levels are inversely correlated with development of atherosclerosis and coronary heart disease (reviewed in Miller, 1987 ). The precise mechanism through which HDL protects however, has not yet been determined. Because of its role in cholesterol metabolism and its inverse correlation with atherosclerosis, the regulation of apolipoprotein A-1 has been extensively studied in a number of dierent model systems.
In mammals, apolipoprotein A1 is expressed predominantly in the liver and intestine (Eisenberg, 1984; Mahley et al., 1984) , whereas in avian species it is expressed in all tissues (Rajavashisth et al., 1987) . The avian tissue distribution matches closely that of mammalian apolipoprotein E which has not yet been identi®ed in chicken. The physiological relevance of this dierence in tissue distribution is not entirely clear. One thought is that avian apolipoprotein A1 may serve dual functions.
The physiological responses that serve to increase or decrease HDL can have a profound eect on long term health. As an example, transgenic mice designed to constitutively express high levels of apolipoprotein A1 were found to be resistant to high cholesterol diet induced atherosclerosis (Rubin et al., 1991; Schultz et al., 1993) suggesting that increased HDL levels had a protective eect . At the other extreme, individuals with non insulin dependent diabetes (NIDDM), exhibit characteristically low levels of apolipoprotein A1 and a signi®cantly higher risk for development of atherosclerosis and coronary heart disease (RoÈ nnemaa et al., 1989; Folin et al., 1993) . Similarly, derangement of cholesterol homeostasis has also been observed in certain types of leukemia. Correlative reports have identi®ed decreased levels of HDL in patients suering from acute lymphocytic leukemia (ALL) (Spiegel et al., 1982; Baroni et al., 1994; Scribano et al., 1996) . Interestingly, HDL levels in these patients was restored to normal levels with successful chemotherapy. These results suggest that decreases in HDL may be a consequence of certain types of oncogenic activity. This eect is likely to exhibit a degree of speci®city dependent on the complement of oncogenes expressed by a particular tumor. Consistent with this idea, we have shown several oncogenes including Myc, v-Src and v-Jun reduce apolipoprotein A1 message levels in CEF whereas others such as Ras and Fos do not ( Figure 5 ). Gene expression of apolipoprotein A-1 is controlled by a number of dierent positive and negative transcriptional control elements. Evidence exists linking glucocorticoids (Varma et al., 1992; Taylor et al., 1996) , members of the retinoic acid receptor family (Rottman et al., 1991; Widom et al., 1992) , HNF4 (Ge et al., 1994) and Egr-1 (Kilbourne et al., 1995) as positive regulatory factors of apolipoprotein A-1 gene transcription. The glucocorticoid receptor does not bind directly to the apolipoprotein A1 promoter and therefore appears to exert its positive eect through an indirect mechanism (Taylor et al., 1996) . In contrast, the orphan nuclear receptor ARP-1 is a strong negative regulator (Ladias and Karathanasis, 1991; Widom et al., 1992; Gaudet and Ginsburg, 1995; Malik and Karathanasis, 1995) . In this report, we demonstrate that v-Jun also is a negative regulator of a apolipoprotein A-1. The mechanism by which this occurs is not clear but a number of direct and indirect mechanisms can be envisioned. For instance, vJun overexpression could result in direct binding of vJun protein complexes to an AP-1 or CREB like negative regulatory element in the promoter of apolipoprotein A-1. Based on published sequence information (Lamon-Fava et al., 1992; , there are no consensus AP-1 elements within this fragment. Therefore, this type of binding would require recognition of a fairly divergent AP-1 or CREB consensus sequence. An equivalent response could occur through v-Jun protein interaction with Erg-1, the glucocorticoid receptor or some other positive regulatory factor to antagonize their binding or quench their positive transcriptional activity. A third possibility is that v-Jun could induce the elevation of a negative regulatory protein such as ARP-1. We are now in the process of sorting out some of these potential regulatory mechanisms in relation to v-Jun induced apolipoprotein A-1 repression.
Materials and methods
Cell culture and transfections
Culture of primary CEF was performed on 10 day old embryos as previously described . The construction of RCAS VJ-1 and RCAS CJ-3 has been described . RCAS vectors containing a cMyc/v-Myc chimera (RCAS c/v Myc), v-Src and murine vHa-Ras (RCAS-BRAS-2-3) were a gift from Stephen Hughes. Construction of RCAS c-Fos was described previously (Hadman et al., 1996) . Transfection of plasmid DNA into CEF was performed using the DMSO polybrene procedure. Virus harvests were at 5 ± 9 days post transfection. Virus was used in subsequent infections to generate CEF expressing various oncogenes.
Plasmid constructions
ApoA-1 genomic CAT plasmids Apolipoprotein A-1 promoter CAT plasmids were generated from a genomic clone of apolipoprotein A-1 obtained from a chicken genomic library. A 7.5 kb XhoI to EcoRI promoter fragment from a positive genomic EMBL3 clone was cloned into Bluescript (Stratagene) to generate p7.5apo-Blue. pCATblue was generated by placing a HindIII to BamHI fragment containing the CAT gene from SV2CAT into Bluescript SK + . Several intermediate plasmids (7300/1293 and 7300/263) were made to facilitate generation of the promoter deletion plasmids shown in Figure 4a . p-300/1293 was obtained from a KpnI digestion and religation of p7.5apoBlue. p-300/ 263apoCAT was obtained from p-300/1293 after digestion with PstI, blunting with T4 polymerase and digestion with BamHI. The vector fragment containing the apolipoprotein gene from 7300 to +263 was then ligated with the CAT gene obtained from digestion of pCAT blue with HindIII/pol 1/BamHI. p-300/20 apoA-1CAT was made using a PCR ampli®ed product obtained with primers against the T7 promoter and apolipoprotein A1 +2 to +19 (CACTGCTCGTCC-CGTGTG) using p-300/263apoCAT as template. The PCR fragment was digested with KpmI and cloned into the HindIII/poll/KpnI site of pCATblue. p-60/20 apoA-1 CAT was generated in a similar manner using PCR primers against 760 to 739 (CTGAAGCTTATCTCCTGCGGGAACTGC) containing a HindIII site and the +2 to +19 primer mentioned above. The PCR product was digested with HindIII and ligated to Bluescript cut with HindIII and BamHI and pCAT blue cut with HindIII/poll/BamHI. p-3300/20 apoA-1 CAT was generated by ligating an Asp 718 promoter fragment spanning 73300 to 7300 with p-300/20 apo A-1 CAT digested with Asp 718.
p-6800 apo A-1 CAT was generated by cloning a HindIII/ XbaI fragment spanning 76800 to 72500 from p7.5apoBlue into a HindIII/XbaI digested p-3300/0 apo A-1 CAT. p-3300/0 apo A-1 CAT was obtained by ligating a Kpn 1 fragment spanning 73300 to 7300 onto p-300/0 apo A-1 CAT. p-300/0 apo A-1 CAT was generated by cloning a KpnI to SacII/pol fragment from p7.5 apo A-1 Blue into a HindIII/ poll/KpnI digested pCAT Blue. p-6000 apo A-1 CAT was generated after ligation of BamHI digested p-6800 apo A-1 CAT fragment spanning, 76000 through the CAT gene, into BamHI digested Bluescript SK(+). p-5000 apo A-1 CAT was generated from ligation of a SacII/KpnI fragment or p-6000 apo A-1 CAT, spanning 75000 to 73300, with a BamHI to KpnI (partial) of p-6000 apo A-1 CAT (which included 73300 of apo A-1 through the CAT gene) and Bluescript digested with BamHI and SacII. p-2500 apo A-1 CAT was generated after religation of a HindIII digest of p-6000 apo A-1 CAT.
CAT assays were performed after transfection of promoter CAT constructs into CEF previously infected either with RCAS vector or RCAS VJ-1. Samples were harvested for CAT activity 3 ± 5 days after transaction.
Library screening and Northern blots
Construction of cDNA libraries, subtraction libraries and dierential screening were done as previously described (Hadman et al., 1996) . A chicken genomic library cloned into a modi®ed EMBL3 vector was obtained from Clontech. A genomic clone of apolipoprotein A-1 was obtained by screening this library using JTAP-4 cDNA as a probe. Northern blots were performed from 10 ± 15 mg total RNA extracted from CEF expressing each of the dierent oncogenes after lysis in guanidinium isothiocyanate. Northern blots were hybridized with probes generated from random primed JTAP-4 cDNA and quantitated by phosphorimage analysis (Molecular Dynamics).
